UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length ...

Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L+ HNSCC – Conference call on Saturday, Dec. 7 at 9:00 a.m. ET to discuss full data ...

SEATTLE, WA / ACCESSWIRE / November 29, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that it will conduct a reverse stock split of its outstanding shares ...

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene ...

Akeso, Inc. (9926. HK) ('Akeso' or the 'Company') is pleased to announce that two of its independently developed, globally ...

UCSF Benioff Children's Hospital Oakland is enrolling patients in an innovative clinical trial that seeks to cure sickle cell ...

Aptevo's Peter Pavlik, PhD, to chair a session on 'Bi and Multispecific Biologics' and will also give talk titled 'Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ ...

Aptevo's Peter Pavlik, PhD, to chair a session on "Bi and Multispecific Biologics" and will also give talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR Plat ...